{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:32:12Z","timestamp":1772728332106,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.ejps.2009.09.017","type":"journal-article","created":{"date-parts":[[2009,10,5]],"date-time":"2009-10-05T12:04:45Z","timestamp":1254744285000},"page":"512-518","source":"Crossref","is-referenced-by-count":32,"title":["The influence of drug\u2013drug interaction and patients\u2019 characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling"],"prefix":"10.1016","volume":"38","author":[{"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Pokrajac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Prostran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017darko","family":"Martinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2009.09.017_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","article-title":"Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses","volume":"32","author":"Ahn","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2009.09.017_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1528-1157.1992.tb02355.x","article-title":"Effect of valproate dose on formation of hepatotoxic metabolites","volume":"33","author":"Anderson","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2009.09.017_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(96)90130-7","article-title":"Bidirectional interaction of valproate and lamotrigine in healthy subjects","volume":"60","author":"Anderson","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003088-198611040-00005","article-title":"Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation","volume":"11","author":"Armijo","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2009.09.017_bib5","series-title":"Pharmacokinetics in Drug Discovery and Development","first-page":"315","article-title":"Population pharmacokinetics","author":"Barett","year":"2002"},{"key":"10.1016\/j.ejps.2009.09.017_bib6","series-title":"Applied Clinical Pharmacokinetics","author":"Bauer","year":"2001"},{"key":"10.1016\/j.ejps.2009.09.017_bib7","series-title":"Stockley's Drug Interactions","author":"Baxter","year":"2006"},{"key":"10.1016\/j.ejps.2009.09.017_bib8","series-title":"NONMEM Users Guides","author":"Beal","year":"1989"},{"key":"10.1016\/j.ejps.2009.09.017_bib9","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2009.09.017_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children","volume":"24","author":"Blanco-Serrano","year":"1999","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data","volume":"20","author":"Blanco-Serrano","year":"1990","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2009.09.017_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2710.2003.00538.x","article-title":"Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implication for dosage","volume":"29","author":"Bondareva","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib13","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1177\/0091270003258670","article-title":"Considerations in anlysing single-trough concentrations using mixed-effects modeling","volume":"43","author":"Booth","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2009.09.017_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2009.09.017_bib15","unstructured":"Drug Interaction Checker. Cerner Multum, Inc., Denver, CO. Available at: http:\/\/www.drugs.com\/drug_interactions.html (accessed May 2008)."},{"key":"10.1016\/j.ejps.2009.09.017_bib16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.1998.00769.x","article-title":"Therapeutic drug monitoring\u2014antiepileptic drugs","volume":"46","author":"Eadie","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2009.09.017_bib17","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","article-title":"Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients","volume":"59","author":"El Desoky","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2009.09.017_bib18","unstructured":"European Medicines Agency (EMEA), Committee for medicinal products for human use (CHMP), 2007. Guideline on reporting the results of population pharmacokinetic analyses. London."},{"key":"10.1016\/j.ejps.2009.09.017_bib19","series-title":"Pharmacotherapy: A Pathophysiologic Approach","first-page":"1023","article-title":"Epilepsy","author":"Gidal","year":"2005"},{"key":"10.1016\/j.ejps.2009.09.017_bib20","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2009.09.017_bib21","first-page":"1576","article-title":"Population pharmacokinetic model of valproate and prediction of valproate serum concentrations in children with epilepsy","volume":"25","author":"Jiang","year":"2004","journal-title":"Acta. Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2009.09.017_bib22","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","article-title":"Population pharmacokinetics of valproate in Chinese children with epilepsy","volume":"28","author":"Jiang","year":"2007","journal-title":"Acta. Pharmacol. Sin."},{"key":"10.1016\/j.ejps.2009.09.017_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0404.2006.00748.x","article-title":"Opinion of Belgian neurologists on antiepileptic drugs: Belgian study on epilepsy treatment (BESET)","volume":"115","author":"Legros","year":"2007","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejps.2009.09.017_bib24","series-title":"Antiepileptic Drugs","first-page":"780","article-title":"Valproic acid: chemistry, biotransformation, and pharmacokinetics","author":"Levy","year":"2002"},{"key":"10.1016\/j.ejps.2009.09.017_bib25","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1528-1157.2002.42401.x","article-title":"Topiramate enhances the risk of valproate-associated side effects in three children","volume":"43","author":"Longin","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2009.09.017_bib26","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00007691-200210000-00009","article-title":"Does lamotrigine influence valproate concentrations?","volume":"24","author":"Mataringa","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2009.09.017_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/1059-1311(92)90037-2","article-title":"Therapeutic drug monitoring improves seizure control and reduces anticonvulsant side-effects in patients with refractory epilepsy","volume":"1","author":"McKee","year":"1992","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2009.09.017_bib28","series-title":"Clinical Pharmacokinetics Pocket Reference","author":"Murphy","year":"2005"},{"key":"10.1016\/j.ejps.2009.09.017_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","article-title":"Population pharmacokinetics of intravenous valproic acid in Korean patients","volume":"27","author":"Park","year":"2002","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2009.09.017_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2710.2005.00671.x","article-title":"Valproate: a simple chemical with so much to offer","volume":"30","author":"Peterson","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2009.09.017_bib33","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1177\/106002809502901113","article-title":"Cigarette smoking and clinically significant drug interactions","volume":"29","author":"Schein","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejps.2009.09.017_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/1099-1263(200011\/12)20:6<427::AID-JAT707>3.0.CO;2-#","article-title":"Effect of benzothiazole on the xenobiotic metabolizizing enzymes and metabolism of acetaminophen","volume":"20","author":"Seo","year":"2000","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejps.2009.09.017_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.ejps.2009.09.017_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J. Pharmacokinet. Biopharmacol."},{"key":"10.1016\/j.ejps.2009.09.017_bib37","unstructured":"USP DI Volume I: Drug Information for the Health Care Professional, 2004, 24th ed. Thomson Micromedex, pp. 709\u2013716, 2781\u20132786."},{"key":"10.1016\/j.ejps.2009.09.017_bib38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FTD.0b013e31815c15f3","article-title":"Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data","volume":"29","author":"Vu\u010di\u0107evi\u0107","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2009.09.017_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01059771","article-title":"Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis","volume":"21","author":"Wade","year":"1993","journal-title":"J. Pharmacokinet. Biopharmacol."},{"key":"10.1016\/j.ejps.2009.09.017_bib40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2710.2003.00528.x","article-title":"Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients","volume":"28","author":"Yukawa","year":"2003","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ejps.2009.09.017_bib41","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","article-title":"Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug\u2013drug interaction and patient characteristics","volume":"37","author":"Yukawa","year":"1997","journal-title":"J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098709002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098709002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T20:58:40Z","timestamp":1558558720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098709002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0928098709002887"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2009.09.017","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}